2017
Updated results of single-agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
Grommes C, Gavrilovic I, Kaley T, Nolan C, Omuro A, Wolfe J, Pentsova E, Hatzoglou V, Mellinghoff I, DeAngelis L. Updated results of single-agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Journal Of Clinical Oncology 2017, 35: 7515-7515. DOI: 10.1200/jco.2017.35.15_suppl.7515.Peer-Reviewed Original ResearchSecondary CNS lymphomaProgression-free survivalMedian progression-free survivalALT elevationCNS lymphomaAdverse eventsClinical responseGrade 4 adverse eventsRecurrent/refractory diseaseAggressive primary brain tumorCerebrospinal fluid involvementCNS lymphoma patientsGrade 5 eventsManageable adverse eventsGrade 3 toxicityMedian overall survivalMethotrexate-based chemotherapyEnd-organ functionNormal end-organ functionSingle-agent ibrutinibUrinary tract infectionPrimary brain tumorsPromising clinical responsesMantle cell lymphomaCommon toxicities
2016
ACTR-12. PHASE I/II STUDY OF SINGLE AGENT IBRUTINIB IN RECURRENT/REFRACTORY PRIMARY (PCNSL) AND SECONDARY CNS LYMPHOMA (SCNSL)
Grommes C, Gavrilovic I, Kaley T, Nolan C, Omuro A, Wolfe J, Pentsova E, Hatzoglou V, Mellinghoff I, DeAngelis L. ACTR-12. PHASE I/II STUDY OF SINGLE AGENT IBRUTINIB IN RECURRENT/REFRACTORY PRIMARY (PCNSL) AND SECONDARY CNS LYMPHOMA (SCNSL). Neuro-Oncology 2016, 18: vi3-vi4. DOI: 10.1093/neuonc/now212.011.Peer-Reviewed Original ResearchSecondary CNS lymphomaCNS lymphomaPhase I/II studyRecurrent/refractory diseaseAggressive primary brain tumorCerebrospinal fluid involvementCNS lymphoma patientsGrade 4 toxicityGrade 3 toxicityEnd-organ functionNormal end-organ functionSingle-agent ibrutinibPrimary brain tumorsPromising clinical responsesB-cell malignanciesCommon toxicitiesEligible patientsFungal encephalitisManageable toxicityMedian PFSMethotrexate regimensPrior therapySCNSL patientsClinical responseII study331PD Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
Grommes C, Gavrilovic I, Kaley T, Nolan C, Omuro A, Wolfe J, Pentsova E, Hatzoglou V, Mellinghoff I, Deangelis L. 331PD Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Annals Of Oncology 2016, 27: vi105. DOI: 10.1093/annonc/mdw367.09.Peer-Reviewed Original ResearchPhase I study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
Grommes C, Kaley T, Nolan C, Omuro A, Wolfe J, Mellinghoff I, DeAngelis L. Phase I study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Journal Of Clinical Oncology 2016, 34: 2046-2046. DOI: 10.1200/jco.2016.34.15_suppl.2046.Peer-Reviewed Original Research
2015
Phase I Study of Single Agent Ibrutinib in Recurrent/Refractory Primary and Secondary CNS Lymphoma
Christian G, Thomas K, Abdel-Wahab O, Omuro A, Ingo M, DeAngelis L. Phase I Study of Single Agent Ibrutinib in Recurrent/Refractory Primary and Secondary CNS Lymphoma. Blood 2015, 126: 3960. DOI: 10.1182/blood.v126.23.3960.3960.Peer-Reviewed Original ResearchRefractory primary CNS lymphomaPrimary CNS lymphomaSecondary CNS lymphomaDose level 2CNS lymphomaCommon grade 2 toxicityRecurrent primary CNS lymphomaRecurrent/refractory diseaseAggressive primary brain tumorCD20 antibody therapyCNS lymphoma patientsDose of ibrutinibGrade 4 toxicityPrior treatment regimensDose level 1Grade 2 toxicityGrade 3 toxicityMethotrexate-based chemotherapyEnd-organ functionNormal end-organ functionSingle-agent ibrutinibPhase I trialPrimary brain tumorsPromising clinical responsesAlternative therapeutic approach